Results 201 to 210 of about 50,045 (313)

Population Modeling of Factor IX Activity Following Administration of Fidanacogene Elaparvovec Gene Therapy in Participants with Hemophilia B. [PDF]

Clin Pharmacokinet
Wojciechowski J, Gaitonde P, Hughes JH, Ravva P.   +3 more
europepmc   +1 more source

Severe hemophilia B [PDF]

, 2020
openaire   +1 more source

Noninvasive prenatal diagnosis for X-linked disease by maternal plasma sequencing in a family of Hemophilia B

, 2017
Ping Hu, Fengchang Qiao, Yuan Yuan, Ruihong Sun, Yan Wang, Lulu Meng, Ying Lin, Hang Li, Yaoshen Wang, Rui Han, Liang Dong, Dingyuan Ma, Tao Jiang, Hui Jiang, Zhengfeng Xu   +14 more
openalex   +1 more source

Extravascular factor IX after gene therapy in hemophilia B, does it matter? [PDF]

Res Pract Thromb Haemost
Van Thillo Q, Hermans C.
europepmc   +1 more source

Mild hemophilia B [PDF]

, 2020
openaire   +1 more source

Natural history of preexisting AAV5 antibodies in adults with hemophilia B during the lead-in of the etranacogene dezaparvovec phase 3 study. [PDF]

Mol Ther Methods Clin Dev
Klamroth R, Recht M, Key NS, Miesbach W, Pipe SW, Kaczmarek R, Drelich D, Salazar B, Le Quellec S, Monahan PE, Galante N, van der Valk P, Tarrant J.   +12 more
europepmc   +1 more source

A Study of AIDS [PDF]

, 1996
Flanagan, Michael B.
core   +1 more source

The Maintenance of Tolerance After Successful Immune Tolerance Induction in Hemophilia A and B: The North American Registry

, 2000
D. DiMichele, Barbara L. Kroner, Aledort, D. I. Michele, Hulman, Mariani, Lenk, Ciavarella, Berntorp, Scandella   +9 more
openalex   +1 more source

Defect in B cell function in HTLV III/LAV positive hemophilia patients [PDF]

, 1987
EJ Sjamsoedin-Visser, CJ Heijnen, Zegers Bj, Stoop Jw   +3 more
openalex   +1 more source

Gene therapy for hemophilia B: results from the phase 1/2 101HEMB01/02 studies. [PDF]

Blood Adv
Pipe S, Poma A, Rajasekhar A, Everington T, Sankoh S, Allen J, Cataldo J, Crombez E.   +7 more
europepmc   +1 more source